Acording to the company, RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise high-density lipoprotein levels thus enhancing HDL functionality to augment reverse cholesterol transport. It is said to be one of the most promising emerging drugs in the treatment of atherosclerosis.
Donald McCaffrey, president and CEO of Resverlogix, said: “The ensuing Phase Ib/IIa study comprises several novel facets to expedite the clinical process for RVX-208 and its eventual registration as a drug.
“Along with the required regulatory provisions that must be addressed such as safety, tolerance and pharmacokinetics, the study also will measure key reverse cholesterol transport markers which RVX-208 impacts.”